BUDZ Highlights Valuable Legacy Genetics Portfolio Following Historic Federal Schedule III Marijuana Action WEED Inc. (OTCQB:BUDZ) Positioned with Rare Landrace Strains as DOJ Announces Immediate Schedule III Pathway for Qualified Medical Marijuana Products

Audio By Carbonatix

TUCSON, AZ / ACCESS Newswire / April 23, 2026 / WEED Inc. (OTCQB:BUDZ) ("BUDZ" or the "Company"), a cannabis bioresearch and genetics-focused public company, today issued a strategic corporate update following the U.S. Department of Justice and Drug Enforcement Administration announcement placing FDA-approved marijuana products and marijuana products subject to qualifying state-issued medical licenses into Schedule III of the Controlled Substances Act, while beginning an expedited hearing process for broader marijuana rescheduling.

The federal announcement is widely viewed as one of the most significant cannabis policy developments in decades and may accelerate medical research, regulated market participation, and long-term institutional interest in the cannabis sector.

"This is a transformational moment for the industry and a validating event for companies like BUDZ that have spent years assembling valuable cannabis, DNA Studies, intellectual property and rare genetics," said Glenn E. Martin, Chief Executive Officer. "We believe our historic strain portfolio now carries even greater strategic relevance in a market moving toward medical cannabis research, legitimacy, and federally recognized medical frameworks."

Rare Legacy Genetics Already Controlled by BUDZ

Through prior acquisitions and internal development initiatives, the Company has assembled a premium collection of recognized heritage and landrace cannabis strains, including;

• Panama Red

• Acapulco Gold

• Red Bud Colombian

• Santa Marta Gold

• Andalusian Nepelese

• Thai (Sticks)

• Israeli Gold (Sativa)

• Afrikan Ebony

• CBD, CBG, and specialty cannabinoid cultivars products from Gummies, Chocolates, Softgels, Oils, Creams. tinctures and topicals

• Infused beverages & edibles

Nicole Breen, Director adds, "I believe these strains represent valuable legacy cannabis branding opportunities, breeding assets, and future product development candidates as legal markets continue maturing. WEED Inc looks to find right partners to further develop its Landrace Strain portfolio. None have been commercially grown ONLY research studies. Now is the time to start opening markets, as U.S.A. will always be The Leadership in Cannabis research & marketplace"

WEED Inc. Legacy name, Title, Symbol, Brands & Strains are known worldwide by generations of cannabis connoisseurs, Glenn E. Martin has been perfecting these strains with close associates for 56 years." Time has not been wasted," CEO Martin added. "As federal policy evolves, authentic genetics and trusted heritage brands WEED believes ours may become some of the most valuable assets in the sector. Currently we have Registered Marks for Panama Red, Acapulco Gold and WEED in several International categories.

Why the DOJ Announcement Matters

The Company believes today's federal Schedule III action may create several key tailwinds:

• Expanded pathways for clinical research and medical studies

• Greater legitimacy for state-regulated medical marijuana programs

• Improved investor sentiment toward public cannabis issuers

• Potential future tax and operating benefits

• New opportunities for licensing, branding, and partnerships

• Momentum toward full broader rescheduling

• Partnership, JV Opportunities

BUDZ believes companies with existing cannabis intellectual property, genetics libraries, and brand equity may be uniquely positioned as the market enters a new phase.

Strategic Focus Going Forward

In response to the shifting landscape, BUDZ is evaluating growth initiatives that may include:

• Legacy strain commercialization

• Medical research partnerships

• Branded premium flower and derivative products

• International genetics licensing

• Wellness and cannabinoid formulation development

• Strategic acquisitions and joint ventures

The Company intends to explore ways to unlock value from its genetics portfolio while supporting responsible medical cannabis innovation.

About WEED Inc:

WEED Inc is a leading cannabis company dedicated to delivering exceptional products and experiences to the cannabis consumer market. With subsidiaries spanning across the USA, the company focuses on innovation, quality, and sustainability Through strategic acquisitions and partnerships, WEED Inc aims to shape the future of the cannabis industry, globally.

Caution Regarding Cannabis Operations in the United States:

Any Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis.

Forward Looking Information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "potential", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to any future revenue and profits.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct.

Actual results and developments may differ materially from those contemplated by these statements.

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release.

That the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws for the relevant country.

Safe Harbor Statement Legal Notice:

That the information is provided for convenience only, it is not investment advice and may not be relied upon in considering an investment in WEED, Inc.

That No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research.

We advise that No representations or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment.

In addition, all prospective investors are encouraged to consult with their financial, tax, accounting, or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

Media Contact:

Glenn E. Martin, CEO

1-520-278-8890

[email protected]

SOURCE: WEED, Inc.